Black Diamond Therapeutics Inc.

2.44+0.0900+3.83%Vol 220.02K1Y Perf -81.08%
Jun 28th, 2022 16:00 DELAYED
BID2.41 ASK2.55
Open2.35 Previous Close2.35
Pre-Market- After-Market2.38
 - -  -0.06 -2.46%
Target Price
5.75 
Analyst Rating
Moderate Buy 2.00
Potential %
135.66 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
8.52 
Earnings Rating
Market Cap88.55M 
Earnings Date
11th Aug 2022
Alpha-0.10 Standard Deviation0.19
Beta1.45 

Today's Price Range

2.282.49

52W Range

1.4612.96

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
13.53%
1 Month
40.72%
3 Months
-14.86%
6 Months
-55.15%
1 Year
-81.08%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BDTX2.440.09003.83
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.75-0.706.67
Q04 2021-1.01-0.7129.70
Q03 2021-0.98-0.971.02
Q02 2021-0.87-0.95-9.20
Q01 2021-0.67-0.84-25.37
Q04 2020-0.63-0.630.00
Q03 2020-0.53-0.505.66
Q02 2020-0.43-0.414.65
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.73
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume220.02K
Shares Outstanding36.29K
Shares Float22.60M
Trades Count1.75K
Dollar Volume532.45K
Avg. Volume437.11K
Avg. Weekly Volume709.62K
Avg. Monthly Volume328.16K
Avg. Quarterly Volume273.56K

Black Diamond Therapeutics Inc. (NASDAQ: BDTX) stock closed at 2.35 per share at the end of the most recent trading day (a 3.52% change compared to the prior day closing price) with a volume of 136.25K shares and market capitalization of 88.55M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 58 people. Black Diamond Therapeutics Inc. CEO is David M. Epstein.

The one-year performance of Black Diamond Therapeutics Inc. stock is -81.08%, while year-to-date (YTD) performance is -55.91%. BDTX stock has a five-year performance of %. Its 52-week range is between 1.46 and 12.96, which gives BDTX stock a 52-week price range ratio of 8.52%

Black Diamond Therapeutics Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 0.48, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.35%, a ROC of -49.83% and a ROE of -53.30%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Black Diamond Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.73 for the next earnings report. Black Diamond Therapeutics Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Black Diamond Therapeutics Inc. is Moderate Buy (2), with a target price of $5.75, which is +135.66% compared to the current price. The earnings rating for Black Diamond Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Black Diamond Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Black Diamond Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.41, ATR14 : 0.19, CCI20 : 108.13, Chaikin Money Flow : 0.09, MACD : 0.05, Money Flow Index : 85.23, ROC : 13.53, RSI : 65.47, STOCH (14,3) : 85.29, STOCH RSI : 1.00, UO : 54.79, Williams %R : -14.71), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Black Diamond Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (50.00 %)
3 (50.00 %)
4 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (50.00 %)
3 (50.00 %)
2 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
1.67

Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform namely, Mutation-Allostery-Pharmacology which is targeting mutations in cancer.

CEO: David M. Epstein

Telephone: +1 617 252-0848

Address: 139 Main Street, Cambridge 02142, MA, US

Number of employees: 58

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

70%30%

Bearish Bullish

64%36%

TipRanks News for BDTX

Wed, 18 May 2022 10:29 GMT Black Diamond Therapeutics (BDTX) Gets a Hold Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Mon, 16 May 2022 10:05 GMT Black Diamond Therapeutics (BDTX) Gets a Buy Rating from Berenberg Bank

- TipRanks. All rights reserved.

Wed, 30 Mar 2022 12:06 GMT Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Black Diamond Therapeutics (BDTX) and Erasca (ERAS)

- TipRanks. All rights reserved.

News

Stocktwits